Official publication of Rawalpindi Medical University
In vitro efficacy of fosfomycin against E. coli and prevalence of MDR and XDR E. coli isolates from UTI Patients

Supplementary Files

PDF

Keywords

Carbapenem resistant, Extensively Drug Resistant, Fosfomycin, Multidrug resistant E. coli, Urinary tract infection

How to Cite

1.
Nasir F, Kashif S, Uddin F, Khalid M, Memon I, Samreen T. In vitro efficacy of fosfomycin against E. coli and prevalence of MDR and XDR E. coli isolates from UTI Patients. JRMC [Internet]. 2023 Apr. 1 [cited 2024 Jun. 14];27(1). Available from: http://www.journalrmc.com/index.php/JRMC/article/view/2002

Abstract

Objective:  The efficacy of fosfomycin against ESBL and/or carbapenem-resistant E. coli isolated from urine samples was determined.

Methodology: Three hundred fifty (350) urine samples were collected from the patients having UTI visited to the department of Urology, JPMC, Karachi. The CLED agar was used for the primary isolation of uropathogens. Regular antimicrobial sensitivity testing was conducted in accordance with CLSI standards, and the minimum inhibitory concentration (MIC) of fosfomycin was assessed using E-strips.

Results: Out of 350 urine samples 213 (60.85%) were E. coli.  Patients with E. coli had an average age of 38.75 15.01 years.  Females are more prone to have UTI 146(68.54%). E. coli was highest among uropathogens having frequency of 213(60.85%). E. coli manifest highest resistance to ampicillin 187(87.79%) and low resistance to meropenem 12(5.63%), imipenem 15(7.51%) and fosfomycin 21(9.85%). The overall carbapenem resistant E. coli was 9(6.4%) and majority of (61.5%) fosfomycin resistant E. coli, MIC value was >1024µg/ml. Isolates were categories in the non-MDR, MDR and XDR. Most of the isolates were MDR (53%), followed by the non-MDR (35%) and XDR (11%).

Conclusion: In conclusion present study suggests that fosfomycin is still effective against E. coli. More than 50% E. coli isolates were MDR and it’s an alarming situation for urologist.  

 

https://doi.org/10.37939/jrmc.v27i1.2002

References

Ito R, Mustapha MM, Tomich AD, Callaghan JD, Mceiheny CL, Mettus RT, Shanks RM, Sluis Cremer N, Doi Y. Widespread Fosfomycin resistance in Gram negative bacteria attributable to the chromosomal fosA gene. mBio 2017; 8(4): e00749-17

Derington CG, Benavides N, Delate T, Fish DN. Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting, Open Forum Infect Dis 2020;7(2):1-8. https://doi.org/10.1093/ofid/ofaa034

Fajfr M, Louda M, Paterova P, Ryskova L, Pacovsky J, Kosina J, Zemlickova H and Brodak M. The susceptibility to fosfomycin of Gram negative bacteria isolates from urinary tract infection in the Czech Republic. BMC Urol 2017; 17(1):33.

Kaase M, Szabados F, Anders A, Gatermann SG. Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J Clin Microbiol 2014;52(6):1893-7. doi: 10.1128/JCM.03484-13.

Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: A first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol 2016; 2082693.

Keepers TR, Gomez MK, Celeri C, Krause KM, Beik D and Critchley I. Fosfomycin and comparator activity against select Enterobacteriaceae, Pseudomonas and Enterococcus urinary tract infection isolates from United States. Infect Dis Ther 2017; 6(2):233-243.

Okhoshi y, Sato T, Suzuki Y, Yamamoto S, Shiraishi T, Ogasawara N and Yokota S. Mechanism of reduced susceptibility to fosfomycin in Escherichia coli clinical isolates. Bio Med Res Intern 2017; 2017:8 pages.

Fransen F, Hermans K, Melchers MJB, Lagarde CCM, Meletiadis J, Mouton JW. Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2017; 72(12):3374-3381

Kandil H, Cramp E and Vaghela Tejal. Trend in antibiotic resistance in urologic practice. Eur Urol Focus 2016; 2(4):363-373.

Linsenmeyer K, Strymish J, Weir S, Berg G, Brecher S and Gupta k. Activity of Fosfomycin against extended spectrum β-lactamase producing uropathogens in patients in the community and hospitalized patients. Antimicrob Agents Chemother 2016; 60(2):1134-1136.

Habeeb MA, Sarwar Y, Ali A, Salman M and Haque A. Rapid emergence of ESBL producers in E. coli causing urinary and wound infections in Pakistan. Pak J Med Sci 2013; 29(2):540-544.

Qamar S, Shaheen N, Shakoor S, Farooqi J, Jabeen K and Hasan R. Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from tertiary care hospital in Karachi. Infect Drug Resist 2017; 10:231-236.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x.

Wang M, Wang W, Niu Y, Liu T, Li L, Zhang M, Li Z, Su W, Liu F, Zhang X and Xu H. A Clinical Extensively-Drug Resistant (XDR) Escherichia coli and Role of Its β-Lactamase Genes. Front. Microbiol 2020;11:590357. doi: 10.3389/fmicb.2020.590357

Ramírez-Castillo, F.Y., Moreno-Flores, A.C., Avelar-González, F.J. et al. An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. Ann Clin Microbiol Antimicrob 2018;17. https://doi.org/10.1186/s12941-018-0286-5

Maher PJ, Brown AE and Gatewood M OK. The effect of written posted instructions on collection of clean catch urine specimen in the emergency department. J Emer Med 2016; 52(5): 639-644.

Coulthard MG. Using urine nitrite sticks to test for urinary tract infection in children aged < 2 years: a meta-analysis. Pediatr Nephrol 2019 34(7):1283-1288. doi: 10.1007/s00467-019-04226-6.

Clinical & Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 28th informational supplement. M100-S28. Wayne, PA: CLSI, 2018.

Sabih A and Leslie SW. Complicated Urinary tract infections. Statpearls internet 2018.

Tenney J, Hudson N, Alnifaidy H, Cheung Li J and Fung KH. Risk factors for acquiring multidrug resistant organisms in urinary tract infections: A systemic literature review. Saudi Pharm J 2018; 26(5): 678-684.

Effah, C.Y., Sun, T., Liu, S. et al. Klebsiella pneumoniae: an increasing threat to public health. Ann Clin Microbiol Antimicrob 2020;9(1). https://doi.org/10.1186/s12941-019-0343-8

Parajuli, N.P., Maharjan, P., Parajuli, H. et al. High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal. Antimicrob Resist Infect Control 2017;6(9). https://doi.org/10.1186/s13756-016-0168-6

Simsek M. Sensitivity of extended spectrum of β-lactamase producing Escherichia coli and Klebsiella species to Fosfomycin. J Pak Med Assoc 2020, 70: 1187-1192. https://doi.org/10.5455/JPMA.32169

Patel B, Patel K, Shetty A, Soman R and Rodrigues C. Fosfomycin susceptibility in urinary tract Enterobacteriaceae. J Assoc Physi India 2017; 65(9):14-16.

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright (c) 2023 Farhina Nasir, Shahida Kashif, Fakhur Uddin, Muhammad Khalid, Ishtiaque Memon, Talat Samreen